City of Hope announces new Hematologic Malignancies and Stem Cell Transplantation InstituteOctober 26, 2014
New institute attracts nationally known experts; wave of novel trials now underway for treatment of lymphoma, myeloma and leukemia
DUARTE, Calif. — Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on researching and treating lymphoma, leukemia and myeloma, as well as other serious blood and bone marrow diseases. Through this institute, laboratory and physician investigators will expand their work and develop new therapies and possible cures for people with leukemia, lymphoma and multiple myeloma.
The Hematologic Malignancies and Stem Cell Transplantation Institute at City of Hope is built upon a foundation that was created by City of Hope’s Stephen J. Forman, M.D., the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at City of Hope, and the leader of the institution’s Hematologic Malignancies Program, and Steven T. Rosen, M.D., the provost and chief scientific officer at City of Hope. Both are known worldwide for the vision, discipline and compassion with which they approach some of the most complex and difficult diseases that afflict men, women and children. Both are committed to continuing to make scientific breakthroughs while caring for patients in the uniquely patient-centered environment for which City of Hope is known.
“Over the years we have seen the development of therapies that, had we known then what we know now, could have saved more lives. The institute will create a collaborative culture of research and individualized care that will accelerate our research breakthroughs for the patients and families who come to us for help,” Forman said.
The institute will be composed of six cornerstone centers. Three will be committed to conducting research that will lead to improved treatments for, respectively, lymphoma, myeloma and leukemia. A fourth will be focused on T cell immunotherapy, with its potential to harness the power of the immune system to treat cancer. A fifth is on stem cell transplantation, building on the international reputation of City of Hope as one of the leading transplant programs in the world for curing people who have cancers of the blood and immune system. A sixth will be dedicated to gene therapy. Two of the centers have already been named: The Toni Stephenson Lymphoma Center, named by Emmet and Toni Stephenson and their daughter, Tessa Stephenson Brand; and the Gehr Family Center for Leukemia Research, named by the Gehr Family Foundation, including Norbert Gehr, and his children, Crystal Gehr, Robert Gehr, Max Gehr and Andrew Gehr.
“City of Hope has already developed a number of new treatment approaches that are now followed by cancer specialists worldwide,” Rosen said. “We are known for being the only center to achieve superior survival outcomes for our transplant patients for nine consecutive years. With the institute, we will be able to do even more for those patients.”
The move to institute status has already led to the recruitment of several internationally recognized clinical and scientific leaders to City of Hope, including Larry W. Kwak, M.D., Ph.D, chairman of the Department of Lymphoma/Myeloma at MD Anderson Cancer Center and associate director of its Center for Cancer Immunology Research; Jasmine Zain, M.D., associate director for the Bone Marrow Transplantation Program at the College of Physicians and Surgeons at the New York Presbyterian Hospital, Herbert Irving Comprehensive Cancer Center at Columbia University; John Chan, M.D., co-director of the Center for Leukemia and Lymphoma Research and co-leader of the Lymphoma Research Program at the University of Nebraska; Guido Marcucci, M.D., professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics in the Division of Hematology at Ohio State University Comprehensive Cancer Center; and Christiane Querfeld, M.D., Ph.D., dermatopathologist/lymphoma specialist at Memorial Sloan-Kettering Cancer Center.
The institute is currently launching several T cell immunotherapy clinical trials for treatment of leukemia and lymphoma, with others being developed for myeloma and novel transplant studies to improve the cure rate for people who need this therapy.
“The institute’s launch is a reflection of City of Hope’s commitment to research and care that changes lives, and the choice of Dr. Forman to lead the institute is a reflection of his remarkable contributions to the field of hematologic malignancies,” said City of Hope’s president and CEO, Robert W. Stone.
“At City of Hope we sincerely believe we have an obligation to transform the lives of as many people as possible. This institute, supported by the generosity and commitment of donors like the Gehr family and Emmet and Toni Stephenson, and their daughter, Tessa Stephenson Brand, will give us the ability to do just that.”
About City of Hope
City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope’s main hospital is located in Duarte, Calif., just northeast of Los Angeles, with community clinics in southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.